HK1199887A1 - Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49 - Google Patents

Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49

Info

Publication number
HK1199887A1
HK1199887A1 HK15100270.4A HK15100270A HK1199887A1 HK 1199887 A1 HK1199887 A1 HK 1199887A1 HK 15100270 A HK15100270 A HK 15100270A HK 1199887 A1 HK1199887 A1 HK 1199887A1
Authority
HK
Hong Kong
Prior art keywords
gpr49
diagnosis
cancer
treatment
antibody
Prior art date
Application number
HK15100270.4A
Other languages
English (en)
Chinese (zh)
Inventor
舟橋真
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of HK1199887A1 publication Critical patent/HK1199887A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
HK15100270.4A 2007-11-14 2015-01-12 Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49 HK1199887A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007295341 2007-11-14

Publications (1)

Publication Number Publication Date
HK1199887A1 true HK1199887A1 (en) 2015-07-24

Family

ID=40638816

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11111677.4A HK1157361A1 (en) 2007-11-14 2011-10-28 Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
HK15100270.4A HK1199887A1 (en) 2007-11-14 2015-01-12 Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11111677.4A HK1157361A1 (en) 2007-11-14 2011-10-28 Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49

Country Status (8)

Country Link
US (2) US8680243B2 (xx)
EP (1) EP2216344B1 (xx)
JP (2) JP5676107B2 (xx)
CN (2) CN104109208A (xx)
AU (1) AU2008321840B2 (xx)
CA (1) CA2705509A1 (xx)
HK (2) HK1157361A1 (xx)
WO (1) WO2009063970A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
WO2013067055A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773664A1 (en) * 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773665A1 (en) * 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773667A1 (en) * 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
US9845356B2 (en) * 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR20160055252A (ko) * 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
CN106459202A (zh) 2014-06-11 2017-02-22 豪夫迈·罗氏有限公司 抗LgR5抗体及其用途
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20220004226A (ko) 2016-03-22 2022-01-11 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
MY191926A (en) 2016-12-01 2022-07-18 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EP3801618A4 (en) 2018-05-30 2022-07-27 National Health Research Institutes ANTI-ABETA ANTIBODIES AND USES THEREOF
AU2019358060A1 (en) * 2018-10-09 2021-04-29 Ibex Biosciences, Inc. Antibodies directed to filamin-A and therapeutic uses thereof
CA3161825A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2001517441A (ja) 1997-09-24 2001-10-09 メルク エンド カムパニー インコーポレーテッド Gタンパク質共役糖タンパク質ホルモン受容体hg38
ES2332025T3 (es) 1998-03-26 2010-01-22 The Board Of Trustees Of The Leland Stanford Junior University Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina.
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
MXPA01011882A (es) 1999-05-25 2002-05-06 Aventis Pharma Sa Productos de expresion de genes implicados en enfermedades relacionadas con el metabolismo del colesterol.
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
JP2005500833A (ja) 2001-06-25 2005-01-13 ブアズーボ・アンパルトセルスカブ 腫瘍学薬物の革新
JP4280814B2 (ja) * 2002-01-17 2009-06-17 国立がんセンター総長 肝がん診断マーカー、肝がんの検出方法、肝がんの診断方法、肝がん分析用定量キット、肝がん細胞スクリーニングキット、肝がん分析方法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
PT1581812E (pt) 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
WO2004074436A2 (en) 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
EP2481814A3 (en) 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
US20090215711A1 (en) 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
JP2007020155A (ja) 2005-06-08 2007-01-25 Canon Inc 画像処理装置、画像処理方法、プログラム、及び記憶媒体
WO2007093008A1 (en) * 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
SI2173379T1 (sl) * 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells

Also Published As

Publication number Publication date
JPWO2009063970A1 (ja) 2011-03-31
JP5986621B2 (ja) 2016-09-06
JP2015134757A (ja) 2015-07-27
CN102112492B (zh) 2015-02-25
US8680243B2 (en) 2014-03-25
AU2008321840A1 (en) 2009-05-22
JP5676107B2 (ja) 2015-02-25
US20110176995A1 (en) 2011-07-21
HK1157361A1 (en) 2012-06-29
CA2705509A1 (en) 2009-05-22
EP2216344A1 (en) 2010-08-11
CN102112492A (zh) 2011-06-29
EP2216344A4 (en) 2010-12-29
WO2009063970A1 (ja) 2009-05-22
US9296823B2 (en) 2016-03-29
US20140147383A1 (en) 2014-05-29
AU2008321840B2 (en) 2014-02-06
CN104109208A (zh) 2014-10-22
EP2216344B1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
HK1199887A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
EP2050466A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-DESMOGLEIN ANTIBODY-3
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
GB0922085D0 (en) Cancer diagnosis and treatment
EP2385114A4 (en) CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
EP1869212A4 (en) USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2171086A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
GB0608647D0 (en) Methods of diagnosis and treatment
EP2115458A4 (en) METHOD FOR DIAGNOSIS OF HEALTH CONDITIONS FOR OVARIAL CARCINOMA AND THE RISK OF HEALTH CONDITIONS IN OVARIAL CARCINOMA
EP2094866A4 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER
EP1989216A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP2377891A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
EP2420515A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
GB2465907B (en) VHZ for diagnosis and treatment of cancer
EP2198041A4 (en) METHOD AND COMPOSITION FOR CANCER DIAGNOSIS AND TREATMENT
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
GB0901837D0 (en) Cancer diagnosis and treatment
EP2515650A4 (en) TARGETED RADIOMARTICATED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER
EP2123676A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
GB0603901D0 (en) Cancer imaging and treatment
HK1209754A1 (en) Compounds and methods for the treatment of cancer